title: Computational design of protein antigens that interact with the CDR H3 loop of HIV broadly neutralizing antibody 2F5.
abstract: Rational design of proteins with novel binding specificities and increased affinity is one of the major goals of computational protein design. Epitope-scaffolds are a new class of antigens engineered by transplanting viral epitopes of predefined structure to protein scaffolds, or by building protein scaffolds around such epitopes. Epitope-scaffolds are of interest as vaccine components to attempt to elicit neutralizing antibodies targeting the specified epitope. In this study we developed a new computational protocol, MultiGraft Interface, that transplants epitopes but also designs additional scaffold features outside the epitope to enhance antibody-binding specificity and potentially influence the specificity of elicited antibodies. We employed MultiGraft Interface to engineer novel epitope-scaffolds that display the known epitope of human immunodeficiency virus 1 (HIV-1) neutralizing antibody 2F5 and that also interact with the functionally important CDR H3 antibody loop. MultiGraft Interface generated an epitope-scaffold that bound 2F5 with subnanomolar affinity (K(D) = 400 pM) and that interacted with the antibody CDR H3 loop through computationally designed contacts. Substantial structural modifications were necessary to engineer this antigen, with the 2F5 epitope replacing a helix in the native scaffold and with 15% of the native scaffold sequence being modified in the design stage. This epitope-scaffold represents a successful example of rational protein backbone engineering and protein-protein interface design and could prove useful in the field of HIV vaccine design. MultiGraft Interface can be generally applied to engineer novel binding partners with altered specificity and optimized affinity.
authors.affiliation: Department of Biochemistry, University of Washington, Seattle, Washington, 98195.
authors.forename: M L
authors.initials: ML
authors.lastname: Azoitei
authors.forename: Y A
authors.initials: YA
authors.lastname: Ban
authors.forename: O
authors.initials: O
authors.lastname: Kalyuzhny
authors.forename: J
authors.initials: J
authors.lastname: Guenaga
authors.forename: A
authors.initials: A
authors.lastname: Schroeter
authors.forename: J
authors.initials: J
authors.lastname: Porter
authors.forename: R
authors.initials: R
authors.lastname: Wyatt
authors.forename: William R
authors.initials: WR
authors.lastname: Schief
mesh_terms: D000595:Amino Acid Sequence; D000818:Animals; D000911:Antibodies, Monoclonal / Q000737:chemistry / Q000235:genetics / Q000378:metabolism*; D057134:Antibodies, Neutralizing / Q000737:chemistry / Q000235:genetics / Q000378:metabolism*; D000914:Antibodies, Viral / Q000737:chemistry / Q000235:genetics / Q000378:metabolism*; D000915:Antibody Affinity; D000918:Antibody Specificity; D000941:Antigens / Q000737:chemistry* / Q000235:genetics / Q000378:metabolism; D000080908:Broadly Neutralizing Antibodies; D022801:Complementarity Determining Regions / Q000737:chemistry* / Q000235:genetics / Q000378:metabolism; D019295:Computational Biology; D000939:Epitopes / Q000737:chemistry / Q000378:metabolism; D015483:HIV Antibodies; D054298:Human Immunodeficiency Virus Proteins / Q000037:antagonists & inhibitors* / Q000737:chemistry / Q000235:genetics / Q000378:metabolism; D020407:Internet; D008958:Models, Molecular; D008969:Molecular Sequence Data; D019151:Peptide Library; D011487:Protein Conformation; D015202:Protein Engineering; D011994:Recombinant Proteins / Q000737:chemistry / Q000378:metabolism; D012984:Software
chemical_list: C558560:2F5 monoclonal antibody; D000911:Antibodies, Monoclonal; D057134:Antibodies, Neutralizing; D000914:Antibodies, Viral; D000941:Antigens; D000080908:Broadly Neutralizing Antibodies; D022801:Complementarity Determining Regions; D000939:Epitopes; D015483:HIV Antibodies; D054298:Human Immunodeficiency Virus Proteins; D019151:Peptide Library; D011994:Recombinant Proteins
keywords: antigen; epitope-scaffold; flexible backbone design; grafting